
Pharmacally
pulmonary arterial hypertension
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in pulmonary arterial hypertension
Health TidingsGossamer Bio Files First NDA for Seralutinib in Pulmonary Arterial HypertensionGossamer Bio has submitted its first New Drug Application to the FDA for inhaled seralutinib in pulmonary arterial hypertension, supported by clinical data from the Phase 3 PROSERA…Fact-Checked
Health TidingsFDA Updates WINREVAIR Label with HYPERION Data in Newly Diagnosed PAHFDA updates the WINREVAIR label with HYPERION data showing a 76% reduction in clinical worsening risk in newly diagnosed pulmonary arterial hypertension.Fact-Checked
Health TidingsFDA Accepts United’s NDA for Ralinepag in Pulmonary Arterial HypertensionThe FDA has accepted United Therapeutics’ NDA for investigational ralinepag for pulmonary arterial hypertension (PAH).Fact-Checked
Health TidingsFDA Clears Path for Gossamer’s Seralutinib NDA Submission in PAHGossamer Bio plans to submit an FDA New Drug Application for seralutinib in pulmonary arterial hypertension in September 2026 after favorable Pre-NDA meeting feedback.Fact-Checked
Clinical TrialsInsmed Report Positive 12-Month Data from the OLE Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Pulmonary Arterial HypertensionInsmed has reported positive 12-month results from the ongoing TPIP open-label extension study in pulmonary arterial hypertension.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.